Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/01/16
End: 11/15/20
Due: 11/15/21
Phase: N/A
Priority: Normal
Start: 02/28/14
End: 04/30/15
Due: 04/30/16
Phase: N/A
Priority: Normal
Start: 05/06/21
End: 01/10/24
Due: 01/10/25
Phase: N/A
Priority: Normal
Start: 04/26/21
End: 12/31/24
Due: 12/31/25
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Assess the Efficacy and Safety of ABTL0812 | NCT03366480 | Ability Pharmaceuticals SL | user2@example.com | None | 2016-12-01 | 2020-11-15 | 2021-11-15 | - | - | 2025-07-14 |
| Phase I/Ib Clinical Trial of ABTL0812 in Advanced Cancer Patients | NCT02201823 | Ability Pharmaceuticals SL | user2@example.com | None | 2014-02-28 | 2015-04-30 | 2016-04-30 | - | - | 2025-07-14 |
| ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study | NCT04431258 | Ability Pharmaceuticals SL | user2@example.com | None | 2021-05-06 | 2024-01-10 | 2025-01-10 | - | - | 2025-07-14 |
| A Study of ABTL0812 in Pancreatic Cancer | NCT03417921 | Ability Pharmaceuticals SL | user2@example.com | None | 2021-04-26 | 2024-12-31 | 2025-12-31 | - | - | 2025-07-14 |